Related Experiment Video
Updated: Apr 25, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Comprehensive validation of machine learning models predicting chemotherapy related electrolyte disorders in a
Nam-Jun Cho1, Inyong Jeong2, Se-Jin Ahn2
1Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
Background:
Electrolyte abnormalities following chemotherapy are common and clinically significant complications in cancer patients and are often associated with treatment delays and adverse outcomes. This study aims to develop and validate machine learning models to predict eight electrolyte abnormalities in cancer patients receiving chemotherapy.
Methods:
We retrospectively analyze medical records of cancer patients from two tertiary hospitals in Korea (n = 11,227). Four machine learning algorithms are used to predict eight electrolyte abnormalities occurring within 4 weeks of chemotherapy initiation. Model performance is evaluated using a comprehensive validation framework, including internal, external, and temporal validation, and model interpretability is assessed using Shapley additive explanations.
Results:
Here we show that electrolyte abnormalities occur in 4451 patients (74.0%) in the internal cohort and 4414 patients (84.7%) in the external cohort, with in-hospital mortality rates of 35.9% and 32.8%, respectively. The best-performing models achieve an average area under the receiver operating characteristic curve of 0.798, with an average performance decline of 0.11 during external validation. Model interpretation identifies serum albumin, heart rate, and estimated glomerular filtration rate as the most important predictors across models. Risk stratification demonstrates that patients in the highest-risk quintile have 4.15-fold greater odds of developing electrolyte abnormalities, and a 2.02-fold higher risk of mortality compared with the moderate-risk.
Conclusions:
These machine learning models provide an effective approach for predicting electrolyte abnormalities in cancer patients receiving chemotherapy and may support risk stratification and monitoring prioritization. Future studies are needed to validate these models in more diverse populations, incorporate additional biomarkers, and explore their integration into clinical decision-support systems.
